Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1

Gemfibrozil (GEM) is a member of the fibrate class of lipid-lowering pharmaceuticals and has been widely used in the therapy of different forms of hyperlipidemia and hypercholesterolemia. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is becoming an important...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaonan, Wang, Song, Hu, Linlin, Wang, Jian, Liu, Yajing, Shi, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327679/
https://www.ncbi.nlm.nih.gov/pubmed/30680004
http://dx.doi.org/10.3892/etm.2018.7046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327679/
https://www.ncbi.nlm.nih.gov/pubmed/30680004
http://dx.doi.org/10.3892/etm.2018.7046

Ejemplares similares